Sodium valproate as a cause of recurrent transudative pleural effusion: a case report
© Tryfon et al; licensee BioMed Central Ltd. 2009
Received: 02 October 2008
Accepted: 09 February 2009
Published: 09 February 2009
There are few reported cases of neutrophilic pleural effusions associated with valproic acid therapy. Most of them are of eosinophilic exudates with or without blood eosinophilia.
This case study describes a 70-year-old man with recurrent episodes of eosinophilic transudative pleural effusions associated with sodium valproate treatment. The recurrence of effusion after re-administration of the drug is strongly suggestive of an association between them. To the best of our knowledge, this is the first reported case with a pleural effusion with these characteristics caused by sodium valproate.
This is the first report in the literature, with a full understanding of the etiology but with an unknown drug mechanism. This case report is of interest to different medical specialists (such as pulmonologists, neurologists, cardiologists) and pharmacologists.
This case study describes a 70-year-old man with recurrent episodes of neutrophilic transudative pleural effusions associated with sodium valproate re-administration. To the best of our knowledge, there are only five reported cases of pleural effusion associated with valproic acid therapy, but this is the first reported case of a pleural effusion with these characteristics.
His past history revealed atrial fibrillation (treated with digoxin), and post-traumatic epilepsy, after a road accident 1 year previously, treated since then with sodium valproate 500 mg/day.
On admission, the patient was febrile, tachypneic and looked moderately ill. Physical examination of the chest showed dullness on percussion at the middle and lower part of the right hemithorax as well as decreased breath sounds. The rest of the clinical examination was unremarkable. Standard laboratory studies demonstrated mild anemia (Ht = 32.2% and Hb = 9.7 mg/dl) and slightly increased erythrocyte sedimentation rate (ESR = 47 mm/h) and C-reactive protein (CRP = 2.8 mg/l). No leukocytosis or eosinophilia was observed. A postero-anterior chest X-ray showed a right-sided pleural effusion. Diagnostic thoracentesis revealed a neutrophilic transudative pleural effusion [total cell count = 100/μl, mainly neutrophils (65%)], glucose = 95 mg/dl, LDH = 30 IU/L, total proteins = 3 g/dl, albumin = 1 g/dl). A therapeutic thoracentesis (drainage of 1200 ml of fluid) resulted in dyspnea relief. Further laboratory investigation, including serum complement analysis, rheumatoid factor, antinuclear antibodies, thyroid hormones, antineutrophilic cytoplasmatic antibodies, immunoglobulin levels, serologic tests for hepatitis A, B and C, as well as for common viruses and atypical infectious agents, disclosed no apparent pathologies. HIV tests were also negative. Serum protein electrophoresis was also normal.
After exclusion of all possible reasons for the observed transudative pleural effusion, sodium valproate was discontinued and replaced with gabapentin (300 mg/day). During this period, the patient did not receive any other medication. Patient follow-up at 15 days, 1 and 2 months after his admission showed no relapse.
Seven months later, the patient had an epileptic episode and he changed his therapy on his own, from gabapentin to sodium valproate again. A month later, he was readmitted to our hospital because of dyspnea, fever, mild anemia with elevated CRP on laboratory tests and a right-sided pleural effusion on chest X-ray. Examination of the pleural fluid showed a transudative effusion with a small number of cells (90/μl), mainly neutrophils (87%).
Sodium valproate was discontinued and gabapentin was re-administered in higher doses (400 mg, twice a day), in order to avoid seizure relapse. This treatment was gradually followed by alleviation of the symptoms, elevation of hematocrit and normalization of CRP. No pleural fluid recurrence was observed after a sequential follow-up, up to 6 months later.
To the best of our knowledge, this is the first reported patient with a transudative pleural effusion due to valproic acid therapy. Adverse reactions to drugs produce only a small percentage of all pleural effusions; however, it is important to consider the possibility of drug-induced pleural disease after the exclusion of all other possible causes.
Valproic acid and its derivative – sodium valproate – are frequently used for the treatment of bipolar disorder, and are also used as an adjunct medication in patients with post-traumatic epilepsy and psychotic disorders such a schizophrenia . Common side effects include nausea, weight gain, somnolence, and tremor. Hepatotoxicity has been reported in some cases. Serum eosinophilia is a possible but usually insignificant side effect.
A review of the literature revealed only five reported cases of pleural effusions associated with valproic acid therapy. Most of them were eosinophilic exudates with or without blood eosinophilia. The first case  referred to a patient with an exudative eosinophilic pleural effusion, which may have been caused by valproic acid or the concomitantly administered antipsychotic medication (chlorpromazine and fluphenazine) or by a potentiation effect. Since valproic acid and antipsychotics were used in combination, medication side effects  or interaction  should be considered as causative mechanisms. Two other case reports [5, 6] described exudative eosinophilic pleural effusions with peripheral blood eosinophilia. No cause of the pleural effusion was found, but on cessation of valproic acid therapy, the pleural effusion and eosinophilia resolved in both patients. The other reported case  referred to a patient with a 'flu-like syndrome' and both pleural and pericardial (non-eosinophilic) effusion after long-term therapy with valproate. The last case was of lymphocytic pleural effusion .
Our patient presented with fever, fatigue, dyspnea and neutrophilic transudative pleural effusions in all three of his hospitalizations. No peripheral eosinophilia was observed. Valproic acid was suggested as the cause of the pleural effusion after exclusion of all other possible causes. Although the clinical picture of the patient, his laboratory blood tests as well as the presence of neutrophils in the pleural fluid suggested an inflammatory reaction, the rest of the characteristics of the pleural effusion were compatible with a transudate. A transudative effusion usually does not imply an inflammation, but instead disequilibrium of the hydrostatic and osmotic driving pressures between the pleural space and the capillary bed of the pleura. This was virtually excluded in our patient, since cardiac and renal functions as well as blood protein levels were all normal. A possible side effect of valproic acid on heart function was excluded as the echocardiography test was normal. Furthermore, it has been reported that intravenous injection of valproate at high concentrations, large doses and fast infusion rates produce no evidence of cardiotoxicity .
The explanation of the presence of a transudative pleural effusion in our patient is obscure. However, the most persuasive evidence that the whole clinical situation was due to the suspected drug was the recurrence of the pleural effusion whenever the regimen was administered and the disappearance of the effusion whenever the drug was discontinued. Indeed, after his final admission, the patient's clinical symptoms subsided with the discontinuation of valproic acid, while no pleural fluid recurrence was observed on follow-up thereafter.
The potential causative mechanism remains elusive, but, still, the recurrence of effusion after re-administration of the drug is strongly suggestive of an association. However, it has been suggested that viral infections (rhinopharyngitis) may induce these adverse events (fever, pleuritis) and additionally may cause clinically significant episodes of thrombocytopenia in these patients . On the other hand, bone marrow suppression and pulmonary hemorrhage have only been reported  in valproate overdoses.
This is the first reported case with a transudative pleural effusion due to valproic acid therapy, and this should be considered after all other possible causative factors have been excluded.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Muller-Oelinghausen B, Retzow A, Henn FA, Giedke H, Walden J, (European Valproate Study Group): Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. J Clin Psychopharmacol. 2000, 20: 195-203. 10.1097/00004714-200004000-00012.View ArticleGoogle Scholar
- Kaufman J, O'Shaughnessy IM: Eosinophilic pleural effusion associated with valproic acid administration. South Med J. 1995, 88: 881-882.View ArticlePubMedGoogle Scholar
- Shear MK: Chlorpromazine-induced PIE syndrome. Am J Psychiatry. 1978, 135: 492-493.View ArticlePubMedGoogle Scholar
- Podolec Z, Vetulani J, Bednarczyk B, Szczeklik A: Central dopamine receptors regulate blood eosinophilia in the rat. Allergy. 1979, 34: 103-110. 10.1111/j.1398-9995.1979.tb01370.x.View ArticlePubMedGoogle Scholar
- Chiles C, Joost van Wattum P: Pleural fluid eosinophilia with combined pharmacotherapy. Psychosomatics. 2003, 44 (5): 436-437. 10.1176/appi.psy.44.5.436.View ArticlePubMedGoogle Scholar
- Kravetz JD, Federman DG: Valproic acid-induced eosinophilic pleural effusion. South Med J. 2003, 96 (8): 803-806. 10.1097/01.SMJ.0000054223.79816.37.View ArticlePubMedGoogle Scholar
- Sleiman C, Raffy O, Roue C, Mal H: Fatal pulmonary haemorrhage during high-dose valproate monotherapy. Chest. 2000, 117 (2): 613-10.1378/chest.117.2.613.View ArticlePubMedGoogle Scholar
- André S, Drowart A, De Bels D: Lymphocytic pleural effusion associated with valproic acid. Eur J Intern Med. 2005, 16 (7): 535-10.1016/j.ejim.2005.02.022.View ArticlePubMedGoogle Scholar
- Gallo BV, Slater JD, Toledo C, DeToledo J, Ramsay RE: Pharmacokinetics and muscle histopathology of intramuscular valproate. Epilepsy Res. 1997, 28 (1): 11-15. 10.1016/S0920-1211(97)00027-2.View ArticlePubMedGoogle Scholar
- Vadney V: Unusual clusters of valproate-associated thrombocytopenia. J Epilepsy. 1992, 5: 186-190. 10.1016/S0896-6974(05)80139-2.View ArticleGoogle Scholar
- Schnabel R, Rambeck B, Janssen F: Fatal intoxication with sodium valproate (letter). Lancet. 1984, 1: 221-222. 10.1016/S0140-6736(84)92140-8.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.